SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 127 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 0.69 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $34,000 | +325.0% | 3,850 | +191.0% | 0.00% | +100.0% |
| Q1 2020 | $8,000 | +33.3% | 1,323 | +80.2% | 0.00% | – |
| Q4 2019 | $6,000 | +20.0% | 734 | +40.1% | 0.00% | – |
| Q3 2019 | $5,000 | +150.0% | 524 | +160.7% | 0.00% | – |
| Q1 2019 | $2,000 | -75.0% | 201 | -72.8% | 0.00% | -100.0% |
| Q4 2018 | $8,000 | +166.7% | 738 | +388.7% | 0.00% | – |
| Q3 2018 | $3,000 | -100.0% | 151 | -77.1% | 0.00% | -100.0% |
| Q2 2018 | $9,372,000 | +34611.1% | 660 | -53.8% | 0.00% | -66.7% |
| Q1 2018 | $27,000 | +92.9% | 1,429 | +63.7% | 0.00% | +200.0% |
| Q4 2017 | $14,000 | +250.0% | 873 | +208.5% | 0.00% | – |
| Q3 2017 | $4,000 | -20.0% | 283 | -52.2% | 0.00% | – |
| Q2 2017 | $5,000 | -28.6% | 592 | -58.6% | 0.00% | -100.0% |
| Q1 2017 | $7,000 | -46.2% | 1,431 | -66.0% | 0.00% | 0.0% |
| Q4 2016 | $13,000 | – | 4,204 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |